Sermorelin: GHRH Research Peptide Guide

<p>Sermorelin (GHRH 1-29 NH2) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH), the form that retains full biological activity. As the shortest fully active GHRH fragment, sermorelin has been studied extensively in research models examining growth hormone axis regulation and pituitary somatotroph function.</p><p>Unlike exogenous recombinant human growth hormone, sermorelin stimulates the pituitary gland's own GH synthesis and release — making it valuable for studying the regulatory mechanisms of the GH axis rather than simply supplementing GH directly.</p><h2>Molecular Profile</h2><p>Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 | MW: 3357.9 g/mol | CAS: 86168-78-7</p><h2>Mechanism and Research Context</h2><p>Sermorelin binds and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs — the same receptor targeted by endogenous GHRH. Receptor activation increases intracellular cAMP, stimulating GH transcription, synthesis, and pulsatile release. Research has used sermorelin to study pituitary responsiveness across age groups in animal models, and as a reference compound in GH secretagogue mechanism studies.</p><p>Sermorelin has a notably short plasma half-life (~10-20 minutes in animal models) due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) at the Ala2 position. This property makes it valuable for studying acute, pulsatile GH dynamics as distinct from sustained secretion models.</p><h2>Research Applications</h2><ul><li>Pituitary somatotroph function and GHRH-R signaling studies</li><li>GH axis responsiveness research in aging animal models</li><li>Comparison studies vs. synthetic GHRH analogs (CJC-1295)</li><li>cAMP pathway activation studies in pituitary cell lines</li><li>Growth hormone kinetics research in preclinical models</li></ul><h2>Frequently Asked Questions</h2><p>Q: Is sermorelin FDA approved?</p><p>A: Sermorelin acetate (brand name Geref) was previously FDA-approved for diagnostic evaluation of GH secretion in children. However, it is no longer commercially available as a pharmaceutical. Research-grade sermorelin is for laboratory use only.</p><p>Q: How does sermorelin differ from CJC-1295?</p><p>A: Both act at the GHRH receptor, but CJC-1295 incorporates structural modifications and optionally DAC technology for significantly extended half-life. Sermorelin has a shorter half-life, producing a more acute pulsatile model.</p><p>Related: Sermorelin Product → | CJC-1295 Research Guide → | Ipamorelin Research Guide → | Tesamorelin Research Guide →</p>